Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EBR Systems, Inc. (EBRCZ)
USD0.27
-0.04 (-11.49%)
US OTC Healthcare Medical - Devices
Address
480 Oakmead Parkway 94085
Sunnyvale, CA, US
Sunnyvale, CA, US
CEO
John Graham McCutcheon
Website
ebrsystemsinc.com
IPO
2023-08-31
CIK 1347123 ISIN AU0000182552
Also trades on
Australian Securities Exchange · EBR.AX (AUD)
Other OTC · EBRCZ (USD)
Description
EBR Systems, Inc. focuses on developing internal medical devices that utilize wireless technology for tissue stimulation. A key offering is their WiSE cardiac resynchronization therapy (CRT) system, which leverages proprietary cable-free technology to deliver electrical pacing directly into the heart's left ventricle. This innovative approach aims to address and eliminate the typical difficulties associated with traditional wired leads, such as challenging insertion, unintended nerve activation, device displacement, complex removal procedures, and the need for frequent repositioning. The company was established in 2003 and operates from its headquarters in Sunnyvale, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.27
-0.04 (-11.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6.1K
Beta
0.55
Float Shares
620.84M
Free Float %
83.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.40% | -7.17% | -22.15% | -41.21% | -45.00% | -72.27% | -39.79% | -39.79% | -39.79% | -39.79% | -39.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.27
Quality scores
Altman Z-Score
-442.45
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%—
-
EPS growth Medical - Devices: +28.5%+0.0% Q1'26: +86.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-3,878.5% Q1'26: -1,003.9% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-2,949.3% Q1'26: -684.7% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-153.9% Q1'26: -162.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+34.1% Q1'26: +20.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.24× Q1'26: -0.94× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 1.50M (-100.0%)
|
—
est: 500.0K (-100.0%)
|
—
est: 125.0K (-100.0%)
|
1.62M
est: 1.32M (+22.9%)
|
16.15M
13.80M – 17.50M
+1,127.4% YoY
|
43.05M
30.70M – 70.90M
+166.6% YoY
|
77.00M
57.88M – 114.98M
+78.9% YoY
|
322.93M
242.75M – 482.22M
+319.4% YoY
|
1.62M
1.22M – 2.41M
-99.5% YoY
|
| EBITDA |
-23.62M
est: 900.0K (-2,725.0%)
|
-24.66M
est: 300.0K (-8,321.6%)
|
-32.06M
est: 75.0K (-42,844.9%)
|
-47.27M
est: 789.5K (-6,087.9%)
|
9.69M
8.28M – 10.50M
+1,127.4% YoY
|
25.83M
18.42M – 42.54M
+166.6% YoY
|
46.20M
34.73M – 68.99M
+78.9% YoY
|
193.76M
145.65M – 289.33M
+319.4% YoY
|
970.2K
729.3K – 1.45M
-99.5% YoY
|
| EBIT |
-39.78M
est: 900.0K (-4,520.4%)
|
-31.20M
est: 300.0K (-10,500.8%)
|
-32.61M
est: 75.0K (-43,579.6%)
|
-47.69M
est: 789.5K (-6,140.8%)
|
9.69M
8.28M – 10.50M
+1,127.4% YoY
|
25.83M
18.42M – 42.54M
+166.6% YoY
|
46.20M
34.73M – 68.99M
+78.9% YoY
|
193.76M
145.65M – 289.33M
+319.4% YoY
|
970.2K
729.3K – 1.45M
-99.5% YoY
|
| Net Income |
-33.09M
est: -31.68M (-4.5%)
|
-35.04M
est: -34.28M (-2.2%)
|
-20.17M
est: -54.98M (+63.3%)
|
-48.76M
est: -48.41M (-0.7%)
|
-45.05M
-73.93M – -30.51M
+6.9% YoY
|
-40.28M
-66.10M – -27.27M
+10.6% YoY
|
-26.30M
-43.17M – -17.81M
+34.7% YoY
|
-33.39M
-54.80M – -22.61M
-26.9% YoY
|
59.89M
40.55M – 98.28M
+279.4% YoY
|
| SGA |
13.51M
est: 3.18M (+324.5%)
|
13.59M
est: 1.06M (+1,180.8%)
|
5.82M
est: 450.0K (+1,192.4%)
|
22.64M
est: 4.74M (+377.9%)
|
58.14M
49.68M – 63.00M
+1,127.4% YoY
|
154.97M
110.52M – 255.23M
+166.6% YoY
|
277.19M
208.36M – 413.91M
+78.9% YoY
|
1.16B
873.85M – 1.74B
+319.4% YoY
|
5.82M
4.38M – 8.69M
-99.5% YoY
|
| EPS |
-122.73
est: -0.11 (-111,818.7%)
|
-121.29
est: -0.11 (-110,003.5%)
|
-0.12
est: -0.13 (+8.9%)
|
-0.12
est: -0.12 (-3.4%)
|
-0.11
-0.18 – -0.07
+6.9% YoY
|
-0.10
-0.16 – -0.07
+10.6% YoY
|
-0.06
-0.10 – -0.04
+34.7% YoY
|
-0.08
-0.13 – -0.05
-26.9% YoY
|
0.14
0.10 – 0.24
+279.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
31.52B
OE per share TTM
79.18
Owner's Yield
21,207.26%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,092.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-5.4K
Shares Outstanding
745.63M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | John McCutcheon President and Chief Executive Officer | 543.8K | — | — | 1.94M | 308.0K | 5.0K | 2.80M | 69.38% | ↗ |
| 2 | 2025 | Erik Strandberg Chief Commercial Officer | 373.8K | — | — | 192.0K | 192.5K | 2.9K | 761.2K | 25.22% | ↗ |
| 3 | 2025 | Gary Doherty Chief Financial Officer | 363.6K | — | — | 240.0K | 132.0K | 5.0K | 740.6K | 32.41% | ↗ |
| 4 | 2024 | John McCutcheon President and Chief Executive Officer | 518.8K | — | — | 588.3K | 316.3K | — | 1.42M | 41.33% | ↗ |
| 5 | 2024 | Erik Strandberg Chief Commercial Officer | 229.2K | 90.7K | — | 650.0K | — | — | 970.5K | 66.98% | ↗ |
| 6 | 2024 | Gary Doherty Chief Financial Officer | 347.8K | — | — | 130.0K | 142.3K | — | 630.0K | 20.63% | ↗ |
| 7 | 2024 | Michael Hendricksen Chief Operating Officer | 324.5K | — | — | 130.0K | 114.7K | — | 569.1K | 22.84% | ↗ |
| 8 | 2023 | Gary Doherty Chief Financial Officer | 108.6K | 43.4K | — | 1.34M | — | — | 1.49M | 89.80% | ↗ |
| 9 | 2023 | John McCutcheon President and Chief Executive Officer | 493.8K | — | — | 209.3K | 241.7K | — | 944.7K | 22.15% | ↗ |
| 10 | 2023 | Michael Hendricksen Chief Operating Officer | 311.3K | — | — | 69.0K | 76.8K | — | 457.1K | 15.10% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Graham McCutcheon | President, Chief Executive Officer & Director | 856.8K | male |
| Erik Strandberg | Chief Commercial Officer | 569.2K | male |
| Gary W. Doherty | Chief Financial Officer | 500.6K | male |
| Michael Hendricksen | Chief Operating Officer | 439.1K | male |
| Allan R. Will | Executive Chairman | 205.0K | male |
| Spencer H. Kubo | Chief Medical Officer | — | — |
| Aimee Einstein | Chief Human Resources Officer | — | female |
| Zheng Li | Company Secretary | — | male |
| Andrew Shute | Chief Corporate Development Officer | — | male |
| N. Parker Willis | Chief Technology Officer | — | — |
| Pharoah Garma | Chief Regulatory Officer | — | female |
| Philip H. Oettinger | Corporate Secretary | — | male |
ESG Rating
ESG Score History MEDICAL - SPECIALTIES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EBRCZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
